Current stock page

Financial Data

HRMY Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

HRMYHarmony Biosciences Holdings, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$33.76−$0.04 (−0.12%)

Latest quote

  • Momentum
    66
  • Value
    89
  • Quality
    77
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$268.92M$261.28M$215.39M$243.78M$239.46M$200.49M$184.73M$201.27M
Gross Profit$188.23M$198.08M$170.88M$175.23M$179.81M$162.34M$152.74M$146.86M
Operating Income$54.2M$89.32M$37.29M$38.56M$65.49M$48.18M$56.25M$55.73M
Net Income$48.2M$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M
EPS$0.83$1.3$0.56$0.39$0.88$0.69$0.8$0.87
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$76.69M$92.43M$27.76M$126.15M$108.73M$79.33M$33.99M$75.56M
Capital Expenditure$0$0$0-$107K-$71K-$4K-$128K-$513K
Free Cash Flow$76.69M$92.43M$27.76M$126.04M$108.66M$79.32M$33.86M$75.05M
Net Cash Provided By Operating Activities$76.69M$92.43M$27.76M$126.15M$108.73M$79.33M$33.99M$75.56M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.48B$1.37B$1.27B$1.27B$1.21B$1.11B$1.06B$999.2M
Total Debt$149.1M$153.96M$206.52M$239.58M$169.73M$173.37M$177.46M$181.41M
Cash And Cash Equivalents$647.1M$549.77M$589.4M$752.5M$647M$546.05M$489M$453M
Total Liabilities$406.01M$373.84M$361.48M$401.41M$373.1M$334.93M$335.01M$340.05M
Total Stockholders Equity$1.07B$999.24M$910.35M$870.22M$835.12M$773.08M$720.53M$659.16M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio10.8512.5712.6810.439.7111.2812.2814.79
P/B ratio1.812.282.031.92.162.642.63.27
P/S ratio1.99———————
Debt To Equity0.140.150.230.280.20.220.250.28
Free Cash Flow Yield16.66%15.57%18.51%21.02%16.46%12.67%11.80%10.16%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio10.8512.5712.6810.439.7111.2812.2814.79
P/B ratio1.812.282.031.92.162.642.63.27
P/S ratio1.99———————
Return On Equity16.66%18.14%16.00%18.24%22.23%23.40%21.20%22.07%
Debt To Equity0.140.150.230.280.20.220.250.28

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe10.96x
Pb1.84x
Revenue Growth Yoy12.30%
EPS Growth Yoy-5.68%
Gross Margin74.03%
Operating Margin22.17%
ROE18.55%
ROIC13.71%
Debt To Equity0.14
FCF Yield16.29%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$33.76
Volume844,895
RSI (14)36.41
MACD-1.42
MACD signal-1.22
MACD histogram-0.2
ADX (14)34.75
SMA (50)$38.65
SMA (200)$34.57
ATR (14)$1.62
Historical volatility (annualized)46.42%
Volume (20-day average)1.22M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score63/100
Beta0.63
Annual volatility40.59%
Max Drawdown-34.49%
Sharpe Ratio0.07
VaR (95%, 1-day)-3.93%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

HRMY Financial Data FAQ

What is Harmony Biosciences Holdings, Inc.'s revenue?

Harmony Biosciences Holdings, Inc.'s revenue is one of the core financial data points for HRMY. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Harmony Biosciences Holdings, Inc.'s revenue growing?

Revenue growth shows whether Harmony Biosciences Holdings, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is HRMY's EPS?

HRMY's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Harmony Biosciences Holdings, Inc.'s net income?

Harmony Biosciences Holdings, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Harmony Biosciences Holdings, Inc. generate?

Free cash flow shows how much cash Harmony Biosciences Holdings, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Harmony Biosciences Holdings, Inc. have?

Cash and debt help frame HRMY's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.